Neuland Laboratories Ltd (NSE:NEULANDLAB) Stock Price, Trades & News

Neuland Laboratories Ltd is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The group has only one reportable segment manufacture of active pharmaceutical ingredients and allied services. It has presence in India, Europe, USA and North America, and Rest of the world.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	1.08
Equity-to-Asset	0.64
Debt-to-Equity	0.16
Debt-to-EBITDA	0.5
Interest Coverage	20.16
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	15.77	Distress Grey Safe
Beneish M-Score	-2.11	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	18.5
	3-Year EBITDA Growth Rate	29
	3-Year EPS without NRI Growth Rate	30.9
	3-Year Book Growth Rate	23.5
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	26.84
	Future 3-5Y Total Revenue Growth Rate Estimate	19.65

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	41.64
	9-Day RSI	47.1
	14-Day RSI	52.16
	3-1 Month Momentum %	25.46
	6-1 Month Momentum %	36.38
	12-1 Month Momentum %	30.95

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.09
	Quick Ratio	1.37
	Cash Ratio	0.46
	Days Inventory	185.49
	Days Sales Outstanding	78.06
	Days Payable	104.2

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.18
	Dividend Payout Ratio	0.04
	3-Year Dividend Growth Rate	33.9
	Forward Dividend Yield %	0.18
	5-Year Yield-on-Cost %	1.39
	Shareholder Yield %	-0.45

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	53.18
	Operating Margin %	23.86
	Net Margin %	17.99
	EBITDA Margin %	29.89
	FCF Margin %	-2.49
	OCF Margin %	17.14
	ROE %	21.76
	ROA %	14.29
	ROIC %	18.22
	3-Year ROIIC %	19.91
	ROC (Joel Greenblatt) %	37.03
	ROCE %	26.42
	Years of Profitability over Past 10-Year	10

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	65.46
	Forward PE Ratio	57.06
	PE Ratio without NRI	65.46
	Shiller PE Ratio	139.21
	Price-to-Owner-Earnings	108.73
	PEG Ratio	1.88
	PS Ratio	11.78
	PB Ratio	12.71
	Price-to-Tangible-Book	15
	Price-to-Operating-Cash-Flow	68.73
	EV-to-EBIT	46.4
	EV-to-Forward-EBIT	14.44
	EV-to-EBITDA	39.36
	EV-to-Forward-EBITDA	10.14
	EV-to-Revenue	11.77
	EV-to-Forward-Revenue	1.64
	EV-to-FCF	-471.75
	Price-to-GF-Value	1.15
	Price-to-Projected-FCF	10.1
	Price-to-DCF (Earnings Based)	2.74
	Price-to-Peter-Lynch-Fair-Value	2.62
	Price-to-Graham-Number	6.61
	Price-to-Net-Current-Asset-Value	55.74
	Earnings Yield (Greenblatt) %	2.16
	FCF Yield %	-0.21
	Forward Rate of Return (Yacktman) %	20.28

Financials (Next Earnings Date:2026-07-31 Est.)

Annual Quarterly TTM

NSE:NEULANDLAB's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Neuland Laboratories Ltd Executives

Details

GF Value™: ₹16161.21

NSE:NEULANDLAB

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Medium warning signs with NEULANDLAB. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil ₹)	20,229.854
	EPS (TTM) (₹)	283.7
	Beta	1.4965
	3-Year Sharpe Ratio	1.32
	3-Year Sortino Ratio	2.71
	Volatility %	39.07
	14-Day RSI	52.16
	14-Day ATR (₹)	557.757465
	20-Day SMA (₹)	18839.1
	12-1 Month Momentum %	30.95
	52-Week Range (₹)	11500 - 20089
	Shares Outstanding (Mil)	12.83

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Neuland Laboratories Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Neuland Laboratories Ltd Stock Events

Financials Calendars

Event	Date	Price (₹)
Second quarter earnings conference call for 2027	2026-11-06 17:30	In 103 days
Second quarter earnings results for 2027	2026-11-06	In 102 days
General meeting for 2026	2026-08-04 10:00	In 9 days
First quarter earnings conference call for 2027	2026-07-31 17:30	In 5 days
First quarter earnings results for 2027	2026-07-31	In 4 days
INR 34.000000 Cash Dividend	2026-07-24	18,431.00 (-0.10%)
Annual report for 2026	2026-07-09	18,889.00 (-0.06%)
Fourth quarter earnings conference call for 2026	2026-05-12 17:30	17,550.00 (-1.23%)
Fourth quarter earnings results for 2026	2026-05-12	17,550.00 (-1.23%)
Third quarter earnings conference call for 2026	2026-02-09 17:30	13,030.00 (-1.47%)

Show

Entries

Neuland Laboratories Ltd Frequently Asked Questions

What is Neuland Laboratories Ltd(NSE:NEULANDLAB)'s stock price today?

The current price of NSE:NEULANDLAB is ₹18546.00. The 52 week high of NSE:NEULANDLAB is ₹20089.00 and 52 week low is ₹11500.00.

When is next earnings date of Neuland Laboratories Ltd(NSE:NEULANDLAB)?

The next earnings date of Neuland Laboratories Ltd(NSE:NEULANDLAB) is 2026-07-31 Est..

Does Neuland Laboratories Ltd(NSE:NEULANDLAB) pay dividends? If so, how much?

The Dividend Yield % of Neuland Laboratories Ltd(NSE:NEULANDLAB) is 0.18% (As of Today), Highest Dividend Payout Ratio of Neuland Laboratories Ltd(NSE:NEULANDLAB) was 0.26. The lowest was 0.03. And the median was 0.05. The Forward Dividend Yield % of Neuland Laboratories Ltd(NSE:NEULANDLAB) is 0.18%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
No Press Release

Articles on Neuland Laboratories Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.